We have developed a multidisciplinary global consortium of researchers who can provide independent high-quality evidence regarding the scale of illicit drug use, harms, access to services at country, regional and global levels, and build capacity for better data in these areas.
The practices of diversion and misuse of pharmaceutical stimulants give serious cause for concern due to their potential to increase the risk of drug toxicity, dependence, and serious adverse health consequences. These practices may be particularly harmful among illicit psychostimulant users.
NDARC has been invited to undertake research in partnership with NSW Aboriginal drug and alcohol Residential Rehabilitation Services. This research is unique in being embedded into the routine delivery of their services.
The Australian National Advisory Council on Alcohol and Drugs (ANACAD) has funded NDARC to conduct a feasibility study for an early warning system (EWS) project, involving a data collection model that allows rapid triangulation of existing data to provide an early warning and current assessment o
Substance use among pregnant women is a significant public health issue. A range of adverse effects have been noted including increased risk of miscarriage and still birth, reduction in fetal growth, birth defects, developmental delay, growth retardation and neurological abnormalities.
With NSW having the largest GLBT community in Australia, it is important that responses to the problems faced by these populations (including a higher risk of drug use and mental health problems) are informed by research evidence.
Substance use amongst adolescents (those in the age group of 10-19) is an important public health issue in many countries of the region.
The overarching objective of this project is to produce as comprehensive as possible an estimate of the costs of methamphetamine use to Australian society. The intention is also to develop an approach that could be applied in a consistent manner to other drugs in the future.
This study aimed to examine the feasibility of agonist maintenance treatment for the major psychoactive drug classes: opioids, nicotine, benzodiazepines, cannabis, psychostimulants and alcohol.